Background: To compare the efficacy and safety of three different chemotherapy doublets in the treatment of advanced pancreatic cancer (PC).
introduction
In 2006, an estimated 33 730 new cases of pancreatic cancer (PC) were diagnosed in USA, and PC is currently the fourth most frequent cause of death from cancer [1] . Despite some progress in chemotherapeutic treatment since the introduction of the nucleoside analog gemcitabine, the prognosis of patients with advanced PC remains very poor [2] . The reported median survival time for patients treated with single-agent gemcitabine in phase III trials ranged from 4.9 to 7.2 months [3, 4] . In the past decade, >15 randomized phase III trials investigated the role of gemcitabine-based combination chemotherapy in advanced PC. In order to improve therapeutic efficacy, standard gemcitabine treatment was mainly combined with antimetabolites, platinum analogs or topoisomerase inhibitors [4] . The most promising results were obtained when gemcitabine was combined with the oral fluoropyrimidine capecitabine or with a platinum compound like cisplatin or oxaliplatin [5] [6] [7] [8] . However, preliminary results of only one of these trials showed a statistically significant survival benefit for original article chemotherapy with gemcitabine plus capecitabine compared with single-agent gemcitabine [8] . Also the combination of gemcitabine with the epidermal growth factor receptor tyrosinekinase inhibitor erlotinib showed a statistically significant survival benefit for the combination regimen [9] . Thus, the optimal combination chemotherapy regimen in advanced PC still remains to be defined. The purpose of this randomized phase II trial was to investigate and exploratively compare the three chemotherapy doublets capecitabine plus oxaliplatin (CapOx), capecitabine plus gemcitabine (CapGem) and a modified gemcitabine plus oxaliplatin (mGemOx) regimen in terms of efficacy and safety in the treatment of patients with advanced PC. Results from phase II and phase III studies evaluating combination chemotherapy with CapGem and GemOx have been reported previously [6-8, 10, 11] . However, the mGemOx regimen used in our trial is different than the one previously reported by Louvet and co-workers [6] : specifically, oxaliplatin is applied on day 8 of a 3-week cycle (instead of day 2 of a 2-week cycle) and gemcitabine is given as a 30-min infusion [not as a fixeddose rate infusion (FDR) of 10 mg/m 2 /min]. This trial is the first randomized comparison of CapOx, CapGem and the mGemOx. To date, there are neither trials comparing the two combinations of mGemOx and CapGem with each other, nor studies that have evaluated the role of a CapOx regimen in the first-line treatment of advanced PC [12, 13] .
patients and methods

patient population
Patients between the age of 18 and 75 years with a histologically confirmed diagnosis of locally advanced (stage III) or metastatic (stage IV) PC not amenable to treatment with curative intent (either by surgery or radiotherapy) were included in this trial. No prior chemotherapy and no prior radiation therapy were allowed. Major eligibility criteria included a bidimensionally measurable lesion according to the World Health Organization (WHO) criteria, a Karnofsky performance status (KPS) of ‡60%, a life expectancy of at least 3 months and adequate bone marrow, hepatic and renal function. Patients with preexisting peripheral neuropathy, known dihydropyrimidine dehydrogenase deficiency or any other malignancy within the past 5 years (except curatively treated basal cell skin cancer or carcinoma in situ of the cervix uteri) were excluded. Pregnant or breast-feeding women and patients unable to use an approved contraceptive method during study treatment were also excluded. The study had approval of the ethical committees in all participating German centers and each patient gave written informed consent before any studyspecific procedure. This study was conducted according to the Declaration of Helsinki.
study design and treatment
This was an open-label, multicenter, three-arm randomized phase II trial. Patients were stratified according to disease stage (locally advanced versus metastatic) and performance status (KPS > 70% versus KPS £ 70%). The primary study end point was progression-free survival (PFS) after 3 months; secondary end points were overall survival (OS), objective response rate (ORR), carbohydrate antigen were carried out on day 1 of each cycle. ORR was evaluated according to the WHO criteria every two cycles (every 6 weeks) using ultrasound, computed tomography and magnetic resonance imaging scans. CBR was defined according to the criteria previously published by Burris et al. [2] : changes in pain (pain intensity and analgesic consumption), KPS and body weight were used to classify patients as responders or nonresponders. Tumor marker response was classified based on a CA 19-9 decline of >20% and >50% after 6 weeks of chemotherapy, respectively [14] . All patients with at least one CA 19-9 measurement at baseline and after two cycles of treatment were included in this analysis. If no CA 19-9 measurement was carried out on day 1 of cycle 3, the CA 19-9 value from day 1 of cycle 4 was used-if available-for determination of CA 19-9 response.
For the determination of PFS and OS, all patients randomized according to the protocol inclusion and exclusion criteria were included. Toxicity analyses were carried out for each patient who received at least one dose of the study drugs according to the protocol. Toxicity was assessed at the beginning of each cycle and classified according to the National Cancer Institute-Common Toxicity Criteria, version 2.0.
baseline KPS as a prognostic factor
Based on recent observations showing an important prognostic role of KPS for patients with advanced PC receiving systemic chemotherapy [5, 15] , a post hoc subgroup analysis was carried out. Patients were separated into groups with a good (KPS ‡90%) and a poor baseline performance status (KPS £ 80%), and the subgroups were analyzed for PFS and OS.
statistical analyses
This trial was designed as a three-arm randomized phase II study. This design was chosen in order to define the most promising regimen, which could be further evaluated in a phase III setting or serve as a platform for future trials incorporating new (e.g. targeted) agents [16] . The primary outcome measure of this study was the PFS rate after 3 months. PFS was defined as the time from random assignment until tumor progression or death. Assuming a PFS rate of 50% after 3 months following treatment with single-agent gemcitabine, a similar finding in this study would be considered as futile. In contrast, we assumed that an experimental combination regimen which achieved a PFS rate of 70% after 3 months would be regarded as a promising candidate for further evaluation. Based on a power of 90% and a type I error rate of 5%, a total population of 150 patients (50 in each arm) was required, with some over recruitment prospectively planned in order to allow for dropouts.
All time-to-event curves for PFS and OS were estimated according to the Kaplan-Meier method, and differences between groups were analyzed using the log-rank test [17] Table 2 . In 25% of all treatment cycles, doses had to be reduced mainly due to treatment-related toxicity. Whereas hematological toxicity was the main reason for dose reduction in the two gemcitabinecontaining treatment arms (84% CapGem, 67% mGemOx, 10% CapOx), non-hematological toxicities were the main causes for dose reduction in the CapOx arm ( Table 2 ). The three main reasons for discontinuation of study treatment were tumor progression (51%), treatment-related toxic effects (19%) and patient refusal (14%). In the mGemOx arm, 26% of patients discontinued treatment due to toxic effects, in the CapOx arm 20% and in the CapGem arm 13%.
efficacy results
response by imaging criteria, CA 19-9 and CBR. Detailed results for ORR, CA 19-9 tumor marker response and CBR are summarized in Table 3 . No complete responses were observed. Partial responses (defined by WHO criteria) were seen in 13% of patients in the two oxaliplatin-containing treatment arms and in 25% of patients in the CapGem arm (P = 0.13).
One hundred and thirty-seven patients were assessable for CBR (CapOx 42, CapGem 52 and mGemOx 43). Based on an intention-to-treat analysis, 11% of patients in the CapOx arm were classified as responders, compared with 23% of patients in the CapGem arm and 30% of patients in the mGemOx arm (Table 3) .
survival results. pfs: At the time of final analysis, 175 of 188 patients (93%) had an event relevant for determination of PFS. Median PFS for all patients was 4.3 months [95% confidence interval (CI) 3.6-5.1], and after 3 months 60% of patients (95% CI 54-68) were alive without tumor progression. PFS results are summarized in Table 4 ; the corresponding Kaplan-Meier plot for PFS is shown in Figure 2A . PFS rate after 3 months, the primary study end point, was 51% in the CapOx arm, 64% in the CapGem arm and 60% in the mGemOx arm. Median PFS was 4.2 months in the CapOx arm, 5.7 months in the CapGem arm and 3.9 months in the mGemOx arm (P = 0.67). Exploratory analysis of possible advantages regarding PFS between the CapGem and CapOx arms (P = 0.42) and between the CapGem and mGemOx arms (P = 0.47) showed no significant differences. original article Annals of Oncology summarized in Table 4 and Figure 2B . Median OS for patients receiving CapOx was 8.1 months, for CapGem 9.0 months and for patients treated with mGemOx 6.9 months (P = 0.56). The corresponding 1-year OS rates were 29%, 33% and 22%, respectively. Survival comparisons in pairs resulted in no significant differences for CapGem versus CapOx (P = 0.82), CapGem versus mGemOx (P = 0.29) and CapOx versus mGemOx (P = 0.46). G1  1  2  2  3  3  5  G2  20  32  25  38  22  35  G3  21  34  17  26  22  35  G4  6  10  1  2  3  5  Unknown  14  23  20  31  13  21 Cap, Capecitabine; Ox, Oxaliplatin; Gem, Gemcitabine; KPS, Karnofsky performance status; CA 19-9, carbohydrate antigen 19-9. subgroup analyses: An exploratory subgroup analysis with determination of PFS and OS by KPS showed a significantly longer median PFS (5.6 versus 3.6 months, P = 0.0081) for patients with a good performance status (KPS ‡ 90% versus KPS £ 80%) at treatment initiation. Patients with a KPS ‡ 90% also showed a prolonged median OS (9.2 versus 7.0 months, P = 0.056). In the subgroup of patients with metastatic disease (n = 154), median PFS by treatment was 3.6 months (95% CI 2.2-5.6) in the CapOx arm, 5.8 months (95% CI 3.0-6.6) in the CapGem arm and 3.8 months (95% CI 2.6-5.1) for mGemOx (P = 0.97). The corresponding median OS times by treatment arm in patients with metastatic disease were estimated to be 7.8 months (CapOx; 95% CI 5.0-10.1), 8.1 months (CapGem; 95% CI 7.1-11.2) and 5.6 months (mGemOx; 95% CI 4.9-8.8), respectively (P = 0.56).
second-line treatment
Overall, 75 (40%) of all randomized patients received secondline chemotherapy after failure of first-line treatment: 47% of patients in the CapOx arm, 34% in the CapGem arm and 38% in the mGemOx arm. In none of the patients with locally advanced disease at study entry, chemoradiotherapy was applied after failure of first-line chemotherapy.
safety results hematological toxicity. Hematological toxicities in each treatment arm are summarized in Table 5 . Myelosuppression was more frequent with the gemcitabine-containing regimens; nevertheless, severe grade 4 hematological toxicities occurred in <15% of patients in all three arms (CapOx 0%, CapGem 13%, mGemOx 13%). By comparing the overall grade 3 and 4 hematological toxicity (maximum per patient) observed in each arm, the CapOx regimen (10%) showed a significant advantage over both the CapGem (35%, P < 0.0001) and the mGemOx (40%, P < 0.0001) regimen.
non-hematological toxicity. Non-hematological toxicity observations are shown in Table 5 . Peripheral neuropathy was more frequent in the two treatment arms including oxaliplatin, whereas there was no clear increase in nausea and vomiting in the two oxaliplatin-containing regimens. By comparing the maximum per patient overall grade 3 and 4 non-hematological toxicity rates, the mGemOx arm was inferior in comparison to the two capecitabine-containing arms (CapOx, 57%; CapGem, 54%; mGemOx, 74%, P = 0.0055).
discussion
This phase II study is the first prospective clinical trial that has compared three different chemotherapy doublets in the For the determination of CA 19-9 response, data from 95 patients were available (CapOx 27, CapGem 38, mGemOx 30). Disease control rate = rate of complete response + partial response + stable disease.
a Global P value = 0.13. b Global P value = 0.26. c Global P value = 0.023.
CA 19-9, carbohydrate antigen 19-9; CBR, clinical benefit response; Cap, Capecitabine; Ox, Oxaliplatin; Gem, Gemcitabine; CI, confidence interval. original article Annals of Oncology treatment of advanced PC. The benefit of combining gemcitabine with a second cytotoxic agent still remains controversial in this disease: phase III trials evaluating the addition of a platinum compound to standard gemcitabine have shown a significant increase in ORR and PFS, but not in OS [5, 6] . Only a preliminary analysis of the trial by Cunningham and co-workers [8] showed a significant increase in median OS for the combination of GemCap when compared to single-agent gemcitabine (7.4 versus 6.0 months, P = 0.026).
In this study, a 4-week regimen for capecitabine was used: capecitabine was given at a total dose of 1660 mg/m 2 /d for 21 days every 4 weeks. In contrast, our trial (capecitabine 1650 mg/m 2 /d for 2 weeks out of three) as well as the phase III study conducted by Herrmann and co-workers [7] (capecitabine 1300 mg/m 2 /d for 2 weeks out of three) used a 3-week regimen. However, the Herrmann study failed to demonstrate a survival benefit for the combination regimen (8.4 versus 7.2 months, P = 0.234) [7] .
The results from a previous phase III trial showed an encouraging median OS for the GemOx regimen (9 months) compared with single-agent gemcitabine (7.1 months, P = 0.13) [6] . Based on these data, the Eastern Cooperative Oncology Group trial E6201 was designed as a three-arm randomized phase III study to answer two questions: first, the effect of administrating gemcitabine by a FDR (1500 mg/m 2 >150 min [18, 19] ) instead of a standard 30-min infusion of 1000 mg/m 2 (Burris regimen); and second, the contribution of oxaliplatin when added to FDR gemcitabine (Louvet regimen) [20] . Preliminary results demonstrated short survival times: median OS in the standard arm with gemcitabine applied as a 30-min infusion was 4.9 months, and both investigational arms showed an increase in OS of about 1 month when singleagent gemcitabine was given as a FDR infusion or when oxaliplatin was added to FDR gemcitabine [20] . In our trial, a median survival time of 6.9 months was achieved with a modified mGemOx regimen.
Possible explanations for varying results between different clinical trials are difficult to assess: reasons may be found, for example, in different drug schedules (e.g. gemcitabine 30-min infusion versus FDR infusion; capecitabine as a 3-week versus 4-week regimen) as well as in differences between patient populations or inter-study variations in second-line treatment, respectively. Even if a comparison of survival results between different randomized trials is rejected as not appropriate, there is at least increasing evidence for an important role of a CapGem regimen in the treatment of advanced PC: median OS for the GemCap combination in the Cunningham trial was 7.4 months, and 8.4 months in the phase III study conducted by Herrmann and co-workers, respectively [7, 8] . However, the Swiss trial did not show statistical superiority for GemCap compared with gemcitabine alone, possibly also due to an underpowered design of the study. Furthermore, the median OS in the control arm (7.2 months) is the longest survival for single-agent gemcitabine ever reported from a phase III trial. The results from our study, with an estimated median PFS of 5.7 months and an OS of 9.0 months for the CapGem regimen, further support these data. Taking these results together-with the known limitations described above-one may possibly favor the CapGem regimen as a platform for further clinical studies (e.g. incorporating targeted agents) in advanced PC. However, based on the statistical study end points, also in our trial none of the experimental regimens met the predefined primary end point (PFS rate after 3 months ‡70%). This is the second randomized trial in advanced PC to incorporate a gemcitabine-free combination chemotherapy arm (CapOx) [21] . CapOx has been studied widely in patients with colorectal cancer and yielded encouraging results, regarding both therapeutic efficacy and toxicity [12, 13] . Based on our data, the efficacy of the CapOx regimen in the treatment of advanced PC seems to be similar to gemcitabine-containing combination regimens. However, the toxicity profile is different with significantly fewer hematological adverse events. Major side-effects of this combination are non-hematological, with neuropathy and hand-foot syndrome being the main reasons for dose reductions (Table 2) . Thus, further studies with CapOx in patients with PC are warranted. As there is still an unclear role of second-line chemotherapy after gemcitabine failure in PC [22] , clinical studies evaluating CapOx in this setting may be a promising approach [23] .
In conclusion, the final results of this randomized trial demonstrate that CapOx, CapGem and the modified mGemOx have similar clinical efficacy according to both primary and secondary study end points. Significant differences were 
